Last reviewed · How we verify

NCT06298292: ZeroMinisMR

Acceptability/Tolerance of Protein Substitutes in Tablet Form for the Dietary Management of Rare Aminoacidopathies

Not yet recruiting Last updated 7 March 2024
What this trial tests

trial testing Zero minis (range of protein substitutes in tablet form) in Tyrosinemia, Type I in 15 participants. Not yet recruiting.

Timeline
1 April 2024
Primary endpoint
31 March 2026
30 June 2026

Quick facts

Lead sponsormetaX Institut fuer Diatetik GmbH
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment15
Start date1 April 2024
Primary completion31 March 2026
Estimated completion30 June 2026

Drugs / interventions tested

Conditions studied

Sponsor

metaX Institut fuer Diatetik GmbH

Who can join

Adults 7 to 18, any sex, with Tyrosinemia, Type I or Tyrosinemia, Type II. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this prospective, observational study is to evaluate the tolerability and acceptability of Zero minis, a range of protein substitute tablets for use in the dietary management of children with either TYROSINAEMIA Type I, II, III or ALKAPTONURIA, HOMOCYSTINURIA, or MAPLE SYRUP URINE DISEASE (MSUD) over the age of 7 years.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other metaX Institut fuer Diatetik GmbH trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06298292.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing